A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
A phase 2 trial of Gemcitabine in endometrial cancer, run by Acrivon Therapeutics, now recruiting.
Overview
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma is a phase 2 interventional study registered as NCT05548296 by Acrivon Therapeutics, with 350 participants planned, started 2022-08-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: ACR-368 and Gemcitabine.
Setting
A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
Phase
Phase 2
Sponsor
Acrivon Therapeutics
Registry
Enrolled
350
Similar pages
not linked directly; found by shared links- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Gemcitabine and the tag pipeline.
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.
- TrialSafety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.
- TrialA Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Shares Gemcitabine and the tag pipeline.